IL197941A0 - Use of anilinopyrimidine derivatives for the preparation of pharmaceutical compositions for treating non-alcoholic liver diseases - Google Patents

Use of anilinopyrimidine derivatives for the preparation of pharmaceutical compositions for treating non-alcoholic liver diseases

Info

Publication number
IL197941A0
IL197941A0 IL197941A IL19794109A IL197941A0 IL 197941 A0 IL197941 A0 IL 197941A0 IL 197941 A IL197941 A IL 197941A IL 19794109 A IL19794109 A IL 19794109A IL 197941 A0 IL197941 A0 IL 197941A0
Authority
IL
Israel
Prior art keywords
preparation
pharmaceutical compositions
liver diseases
alcoholic liver
treating non
Prior art date
Application number
IL197941A
Other languages
English (en)
Original Assignee
Dreano Michel
Ares Trading Sa
Beraza Naiara
Trautwein Christian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dreano Michel, Ares Trading Sa, Beraza Naiara, Trautwein Christian filed Critical Dreano Michel
Publication of IL197941A0 publication Critical patent/IL197941A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL197941A 2006-10-04 2009-04-05 Use of anilinopyrimidine derivatives for the preparation of pharmaceutical compositions for treating non-alcoholic liver diseases IL197941A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84925106P 2006-10-04 2006-10-04
US90411607P 2007-02-28 2007-02-28
PCT/EP2007/008627 WO2008040548A2 (en) 2006-10-04 2007-10-04 Treatment for non-alcoholic-steatohepatitis

Publications (1)

Publication Number Publication Date
IL197941A0 true IL197941A0 (en) 2009-12-24

Family

ID=38949734

Family Applications (1)

Application Number Title Priority Date Filing Date
IL197941A IL197941A0 (en) 2006-10-04 2009-04-05 Use of anilinopyrimidine derivatives for the preparation of pharmaceutical compositions for treating non-alcoholic liver diseases

Country Status (7)

Country Link
US (1) US20080194575A1 (enExample)
EP (1) EP2157975A2 (enExample)
JP (1) JP2010505783A (enExample)
AU (1) AU2007304439A1 (enExample)
CA (1) CA2664413A1 (enExample)
IL (1) IL197941A0 (enExample)
WO (1) WO2008040548A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
US8524212B2 (en) * 2007-10-24 2013-09-03 Mitsubishi Tanabe Pharma Corporation Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis
US20100008988A1 (en) * 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
EP2488180A4 (en) * 2009-10-12 2013-03-27 Ipca Lab Ltd PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT / PROPHYLAXIS OF NON ALCOHOLIC HEPATIC STEATOSIS
MX2012014158A (es) 2010-06-04 2013-02-07 Hoffmann La Roche Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
PH12013500880A1 (en) 2010-11-10 2013-07-01 Hoffmann La Roche Pyrazole aminopyrimidine derivatives as lrrk2 modulators
US8865641B2 (en) 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
MX360979B (es) * 2011-09-16 2018-11-22 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
JP6556825B2 (ja) * 2014-03-21 2019-08-07 トビラ セラピューティクス， インコーポレイテッド 線維症を処置するためのセニクリビロック
CA2968215A1 (en) * 2014-08-20 2016-02-25 Yale University Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
US10328122B2 (en) * 2015-09-15 2019-06-25 Zhejiang University Method of treating fulminant hepatic failure using DLL4 cytokine
JP7065786B2 (ja) * 2016-04-21 2022-05-12 シーエスエル リミティド 肝病態を治療又は予防する方法
US20170319540A1 (en) * 2016-05-06 2017-11-09 Vivus, Inc. Methods and Compositions for the Treatment of Non-Alcoholic Steatohepatitis
EP3278802A1 (en) * 2016-08-04 2018-02-07 Metabolys New treatment for the non alcoholic steatohepatitis and fibrosis
GB201614455D0 (en) * 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
TW201818964A (zh) * 2016-09-30 2018-06-01 瑞士商諾伊曼特醫療公司 使用色胺酸羥化酶抑制劑之方法
WO2018148250A1 (en) * 2017-02-07 2018-08-16 The Regents Of The University Of California Methods for inhibiting nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis
JPWO2020090967A1 (ja) * 2018-10-31 2021-09-16 東和薬品株式会社 線維化誘導遺伝子の発現抑制剤およびその用途
CN114555076B (zh) * 2019-10-18 2024-02-02 正大天晴药业集团股份有限公司 用于治疗非酒精性脂肪性肝炎的药物
CN113087757A (zh) * 2021-03-12 2021-07-09 济南大学 一种5α结构的乙型强心苷的制备及其抗肝癌应用
KR102684334B1 (ko) * 2021-08-18 2024-07-12 제이투에이치바이오텍 (주) 지방간염, 지방증 또는 섬유증의 예방 또는 치료용 복합 제제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
EP1390052A4 (en) * 2001-04-24 2008-10-08 Harvard College INHIBITION OF JUN KINASE
AU2004207444B2 (en) * 2003-01-17 2008-07-31 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
US20050266391A1 (en) * 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
CA2623025A1 (en) * 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist

Also Published As

Publication number Publication date
AU2007304439A1 (en) 2008-04-10
US20080194575A1 (en) 2008-08-14
WO2008040548A3 (en) 2009-05-22
CA2664413A1 (en) 2008-04-10
JP2010505783A (ja) 2010-02-25
AU2007304439A2 (en) 2009-04-23
EP2157975A2 (en) 2010-03-03
WO2008040548A2 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
IL197941A0 (en) Use of anilinopyrimidine derivatives for the preparation of pharmaceutical compositions for treating non-alcoholic liver diseases
IL200116A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
IL195491A (en) Pharmaceutical preparations containing tmc278 and processes for their preparation
ZA200900347B (en) Preparation of pharmaceutical compositions
IL221764A (en) Use of bile acid sulfate to make pharmaceutical preparations for the treatment of fxr-related diseases
IL199853A (en) Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them
IL195611A0 (en) Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown
IL210319A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
IL192763A (en) History of pyrimidine, preparations containing them and used in the preparation of cancer drugs
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
IL196280A0 (en) Use of ampk-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
IL197877A (en) Uses of aminomethyl-4-imidazole derivatives for the preparation of medications and medications containing them
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
IL194961A0 (en) Compounds a-r-x for the manufacture of pharmaceutical preparations
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
IL181827A0 (en) Donepezil salts suitable for the preparation of pharmaceutical compositions
EP1938842A4 (en) METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
IL183930A0 (en) Use of cladribine for preparation of pharmaceutical compositions
EP2213303A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
ZA201009072B (en) Pharmaceutical composition for the treatment of premature ejaculation
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
PL2331092T3 (pl) Sposoby i kompozycje do podawania 3-halopirogronianiu i związków pochodnych w leczeniu nowotworu
WO2007139833A3 (en) Imidazoazephinone compounds
IL188831A0 (en) Compositions for reducing the incidence of drug induced arrhythmia